The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects

The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3‐isopropylpyrazolyl)borate (Tp(iPr)), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Berasaluce, Iker, Cseh, Klaudia, Roller, Alexander, Hejl, Michaela, Heffeter, Petra, Berger, Walter, Jakupec, Michael A., Kandioller, Wolfgang, Malarek, Michael S., Keppler, Bernhard K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064950/
https://www.ncbi.nlm.nih.gov/pubmed/31560142
http://dx.doi.org/10.1002/chem.201903605
_version_ 1783504966588039168
author Berasaluce, Iker
Cseh, Klaudia
Roller, Alexander
Hejl, Michaela
Heffeter, Petra
Berger, Walter
Jakupec, Michael A.
Kandioller, Wolfgang
Malarek, Michael S.
Keppler, Bernhard K.
author_facet Berasaluce, Iker
Cseh, Klaudia
Roller, Alexander
Hejl, Michaela
Heffeter, Petra
Berger, Walter
Jakupec, Michael A.
Kandioller, Wolfgang
Malarek, Michael S.
Keppler, Bernhard K.
author_sort Berasaluce, Iker
collection PubMed
description The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3‐isopropylpyrazolyl)borate (Tp(iPr)), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed include (O,O‐) (S,O‐) (N,N‐) donors that have been successfully coordinated to the molybdenum center by means of oxygen‐atom transfer (OAT) reactions from the known Mo(VI) starting material, Tp(iPr)MoO(2)Cl. The synthesized complexes were characterized by standard analytical methods and where possible by X‐ray diffraction analysis. The aqueous stability of the compounds was studied by means of UV/Vis spectroscopy and the impact of the attached ligand scaffolds on the oxidation potentials (Mo(IV) to Mo(V)) was studied by cyclic voltammetry. Utilizing polyvinylpyrrolidone (PVP) as a solubilizing agent, adequate aqueous solubility for biological tests was obtained. Anticancer activity tests and preliminary mode of action studies have been performed in vitro and in vivo.
format Online
Article
Text
id pubmed-7064950
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70649502020-03-16 The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects Berasaluce, Iker Cseh, Klaudia Roller, Alexander Hejl, Michaela Heffeter, Petra Berger, Walter Jakupec, Michael A. Kandioller, Wolfgang Malarek, Michael S. Keppler, Bernhard K. Chemistry Full Papers The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3‐isopropylpyrazolyl)borate (Tp(iPr)), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed include (O,O‐) (S,O‐) (N,N‐) donors that have been successfully coordinated to the molybdenum center by means of oxygen‐atom transfer (OAT) reactions from the known Mo(VI) starting material, Tp(iPr)MoO(2)Cl. The synthesized complexes were characterized by standard analytical methods and where possible by X‐ray diffraction analysis. The aqueous stability of the compounds was studied by means of UV/Vis spectroscopy and the impact of the attached ligand scaffolds on the oxidation potentials (Mo(IV) to Mo(V)) was studied by cyclic voltammetry. Utilizing polyvinylpyrrolidone (PVP) as a solubilizing agent, adequate aqueous solubility for biological tests was obtained. Anticancer activity tests and preliminary mode of action studies have been performed in vitro and in vivo. John Wiley and Sons Inc. 2019-11-19 2020-02-17 /pmc/articles/PMC7064950/ /pubmed/31560142 http://dx.doi.org/10.1002/chem.201903605 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Full Papers
Berasaluce, Iker
Cseh, Klaudia
Roller, Alexander
Hejl, Michaela
Heffeter, Petra
Berger, Walter
Jakupec, Michael A.
Kandioller, Wolfgang
Malarek, Michael S.
Keppler, Bernhard K.
The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
title The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
title_full The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
title_fullStr The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
title_full_unstemmed The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
title_short The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
title_sort first anticancer tris(pyrazolyl)borate molybdenum(iv) complexes: tested in vitro and in vivo—a comparison of o,o‐, s,o‐, and n,n‐chelate effects
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064950/
https://www.ncbi.nlm.nih.gov/pubmed/31560142
http://dx.doi.org/10.1002/chem.201903605
work_keys_str_mv AT berasaluceiker thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT csehklaudia thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT rolleralexander thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT hejlmichaela thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT heffeterpetra thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT bergerwalter thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT jakupecmichaela thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT kandiollerwolfgang thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT malarekmichaels thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT kepplerbernhardk thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT berasaluceiker firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT csehklaudia firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT rolleralexander firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT hejlmichaela firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT heffeterpetra firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT bergerwalter firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT jakupecmichaela firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT kandiollerwolfgang firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT malarekmichaels firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects
AT kepplerbernhardk firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects

Ejemplares similares